The Bio Report
Reprogramming T Cells to Cross the Brain’s Border
The Bio Report
•February 4, 2026•38 min
0
The Bio Report•Feb 4, 2026
Why It Matters
Crossing the blood‑brain barrier remains a major bottleneck in treating aggressive brain cancers, so a safe, effective delivery system could dramatically improve patient outcomes. By using autologous T cells, Adaptin’s approach may offer a scalable, less invasive alternative to current methods, making it a timely development for both clinicians and biotech investors focused on neuro‑oncology.
AI Summary
In this episode, host and guest Michael Roberts, co‑founder and CEO of Adaptin Bio, discuss the difficulty of delivering biologic therapies across the blood‑brain barrier for glioblastoma patients. Roberts explains Adaptin’s platform, which reprograms a patient’s own T cells to act as carriers for bispecific therapeutic payloads, enabling them to cross the barrier and target tumor cells directly. He highlights the limitations of existing delivery methods, such as invasive surgery or nanoparticle approaches, and how the T‑cell strategy could improve efficacy while reducing side effects. The conversation underscores the potential to shift the treatment paradigm for brain tumors by leveraging the body’s immune cells as precision delivery vehicles.
Episode Description
One of the challenges of treating brain tumors is delivering potent biologic therapies across the blood-brain barrier. Adaptin Bio has developed platform technology that harnesses a patient’s own T cells to transport bispecific therapeutic payloads across the blood-brain barrier and into other targeted tissue with an initial focus on treating glioblastoma. We spoke to Michael Roberts, co-founder and CEO of Adaptin Bio, about the unmet need in glioblastoma, the limitations of current blood-brain barrier–crossing strategies, and how the company’s platform seeks to change the treatment paradigm by using patient-derived T cells as delivery vehicles for targeted biologics.
Show Notes
0
Comments
Want to join the conversation?
Loading comments...